PHAR Stock Analysis: Buy, Sell, or Hold?
PHAR - Pharming Group N.V. ADS, each representing 10 ordinary shares
$9.93
-0.15 (-1.47%)
▼
5d:
-23.68%
30d:
-27.88%
90d:
-41.51%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When PHAR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PHAR is down 23.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PHAR is down 23.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: PHAR is currently trading at $9.93, which is considered oversold relative to its 30-day fair value range of $11.95 to $14.22. From a valuation perspective, the stock is trading at a discount (Forward PE: 153.9) compared to its historical average (216.1). Remarkably, the market is currently pricing in an annual earnings decline of 10.7% over the next few years. This pessimistic expectation contrasts with the company's recent 104.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, PHAR is in a strong downtrend. Immediate support is located at $9.62, while resistance sits at $13.40.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $34.35 (+240.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PHAR is in a strong downtrend. Immediate support is located at $9.62, while resistance sits at $13.40.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $34.35 (+240.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$11.95 -
$14.22
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 240.8% below Wall St target ($34.35)
- WARNING: Recommendation downgraded due to -23.7% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$11.95 -
$14.22
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$9.62
Resistance Level
$13.40
Current Trend
Strong Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
153.89
Wall Street Target
$34.35
(+240.8%)
Revenue Growth (YoY)
-8.4%
Earnings Growth (YoY)
104.2%
Profit Margin
3.3%
Valuation Discount vs History
-10.7% cheaper
PE vs Historical
153.9 vs 216.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-10.7%
(market-implied from PE analysis)
1-Year Target
$9.07
(-10%)
2-Year Target
$8.16
(-19%)
3-Year Target
$7.35
(-27%)
3-Yr Target (if PE normalizes)
(PE: 154→216)
$10.32
(+2%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 153.9, Growth: -71.6%)
$7.35
(+-27%)
Base:
(SPY PE: 20.7, Growth: -71.6%)
$0.99
(-90%)
Bear:
(PE: 17.6, Growth: -71.6%)
$0.84
(-92%)
📈
Valuation based on Current Earnings
Forward PE: 22.42 | Forward EPS (Implied): $0.45
Bull Case
$12.17
(+21%)
Analyst growth 15.0%, PE expands to 23.5
Base Case
$10.08
(0%)
Market implied 0.0%, PE stable at 22.4
Bear Case
$7.71
(-24%)
Severe decline -15.0%, PE contracts to 20.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 153.9 to 216.1
Stabilization Target:
$14.15
(+40.4%)
PE Expansion Potential:
+40.4%
Share & Embed Analysis
Last updated: August 03, 2026 3:41 PM ET
Data refreshes hourly during market hours. Next update: 4:41 PM
Data refreshes hourly during market hours. Next update: 4:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHAR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$87 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$196 | 47 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 47 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 51 HOLD |
